Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Insmed (INSM) EBITDA (2016 - 2026)

Insmed's EBITDA history spans 17 years, with the latest figure at -$165.0 million for Q1 2026.

  • Quarterly EBITDA rose 35.34% to -$165.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 16.82% year-over-year, with the annual reading at -$1.3 billion for FY2025, 39.08% down from the prior year.
  • EBITDA came in at -$165.0 million for Q1 2026, up from -$329.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$95.8 million in Q1 2022 to a low of -$369.8 million in Q3 2025.
  • The 5-year median for EBITDA is -$184.7 million (2023), against an average of -$211.0 million.
  • Year-over-year, EBITDA crashed 156.52% in 2023 and then surged 35.34% in 2026.
  • Insmed's EBITDA stood at -$158.0 million in 2022, then dropped by 16.93% to -$184.7 million in 2023, then dropped by 29.05% to -$238.4 million in 2024, then plummeted by 38.02% to -$329.0 million in 2025, then soared by 49.85% to -$165.0 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's EBITDA are -$165.0 million (Q1 2026), -$329.0 million (Q4 2025), and -$369.8 million (Q3 2025).